coming soon

Rice University launches research innovation grant program with VC fund in the works

Rice University has launched the One Small Step Grant program and has plans to establish the One Giant Leap VC fund. Photo courtesy of Rice University

Over 60 years ago at Rice University, President John F. Kennedy recommitted the country to the Space Race. Now, decades later, the university is announcing its commitment to moonshot innovators.

Rice University's Office of Innovation established the One Small Step Grant — named for Neil Armstrong's first words spoken from Tranquility Base just several years after JFK's speech at Rice — last month. The program will provide funding to faculty working on "promising projects with commercial potential," according to the website.

The grant initiative will provide as many as five awards a year, each with funding of up to $100,000. Applications, which are open now, are accepted on a rolling basis, and the university's Rice Investment Committee will review submissions on a quarterly basis.

"The One Small Step Grant is a beacon of hope by providing support to enable critical experiments that pave the way for groundbreaking startups or licensing breakthrough tech," reads the website. "We seek projects within 12-18 months of forming a spin-out or embarking on a licensing event."

Paul Cherukuri, vice president of innovation at Rice University, shared the news of the grant program at an August 28 panel for the opening of Houston Methodist's Tech Hub at the Ion.

He says the initiative comes out of the need to financially support faculty-led, research-focused projects and to incentivize these faculty members to take their innovative ideas and commercialize them. Since he took on his role at Rice a year ago, he's observed the need for this type of funding.

"As soon as we announced this, in the same day, we had five professors fill out the form," Cherukuri says about the One Small Step Grant program.

The initiative has two parts to it, with the new grant program being the first to deliver. Next will be the One Giant Leap Fund, which Rice has not yet revealed details on.

Paul Cherukuri, vice president of innovation at Rice University, shared details about the new program at a recent event at the Ion. Photo via Rice.edu

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted